Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06271057
Other study ID # CARMOD
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date April 22, 2024
Est. completion date October 20, 2027

Study information

Verified date February 2024
Source The Lymphoma Academic Research Organisation
Contact Stéphanie DOYEN
Phone +33 4 27 01 27 36
Email stephanie.doyen@lysarc.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is an open-label, multicenter, proof of concept, phase 2 trial. Patients will be recruited over 18 months. Safety analysis will be performed with a stop of the enrollment after 3 patients have either 1 complete treatment cycle or permanently discontinued treatment whichever occurs first. Approximatively 65 patients with aggressive large B-cell lymphoma (LBCL) (including diffuse large B-cell lymphoma (DLBCL), Primary mediastinal B-cell lymphoma (PMBCL), any transformed follicular or marginal zone lymphoma, high-grade B-cell lymphoma (HGBL)) will be enrolled in the study. The duration of treatment with golcadomide (CELMoD) is 24 weeks with 6 cycles of 28 days (4 weeks), starting at 5 days after CAR-T cells infusion. The primary objective of the study is to estimate the efficacy of golcadomide administered post-anti-CD19 CAR T-cell infusion, Efficacy determination will be based upon the primary endpoint of complete metabolic response (CMR) rate at 3 months after infusion of anti-CD19 CAR T-cell assessed by study investigator.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 65
Est. completion date October 20, 2027
Est. primary completion date January 15, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patient who understood and voluntarily signed and dated an informed consent prior to any study-specific assessments/procedures being conducted 2. Adults patients (= 18-year-old at the time of signing the informed consent form; no upper age limit) 3. Eligible for any commercialized market authorized anti-CD19 CAR T-cells 4. Performance Status 0 or 1 5. With aggressive large B-cell lymphoma, including: - diffuse large B-cell lymphoma - Primary mediastinal B-cell lymphoma - Any transformed follicular or marginal zone lymphoma - high-grade B-cell lymphoma (HGBL) Note: patients with Central Nervous System (CNS) involvement could be included but not patients with primary CNS lymphoma 6. Available biopsy for centralized review 7. With a CAR T-cells indication as soon as 2nd line treatment no later than in 4th line, previously validated by the multidisciplinary tumor board Note: Any treatment performed prior to leukapheresis is considered a line of treatment 8. Total MetabolicTumor Volume (TMTV) > 80 ml, measured by centralized review, on 18FDG-PET (positron emission tomography) done just before starting CAR T-cells procedure (i.e., D-13 +/- 4 days before CAR-T cells infusion) 9. Creatinine clearance (as estimated by Modification of Diet in Renal Disease (MDRD) if > 60-year-old or Cockcroft-Gault if <60yo) >45 mL/min, 10. Adequate hepatic function: - aspartate aminotransferase/alanine aminotransferase (ALT/AST) = 3.0 x ULN. (Note: In the case of documented liver involvement by lymphoma, ALT/AST must be = 5.0 x ULN) - Serum total bilirubin = 2.0 mg/dL (34 µmol/L) (Note: In the case of Gilbert's syndrome, or documented liver or pancreatic involvement by lymphoma, serum total bilirubin must be = 3.0 mg/dL (51 µmol/L)) 11. Patient covered by any social security system (France) 12. Patient who understands and speaks one of the country official languages, unless local regulation authorizes independent translators 13. Contraception: - For women of childbearing potential: Agreement to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of contraception, including at least one method with a failure rate of <1% per year, as soon as consent is signed, during the treatment period (including periods of treatment interruption), and for at least 28 days after the last dose of golcadomide, Women must refrain from donating eggs during this same period. Exclusion Criteria: 1. History of malignancy other than non-melanoma skin cancer or carcinoma in situ (eg, cervix, bladder, breast) unless disease free for at least 3 years 2. Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management; simple urinary tract infection and uncomplicated bacterial pharyngitis are permitted if responding to active treatment and after consultation with the sponsor's medical monitor 3. History of human immunodeficiency virus (HIV) infection or acute or chronic active hepatitis B or C infection; subjects with history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America guidelines or applicable country guidelines 4. Significant pulmonary function impairment and oxygen saturation (SaO2) < 92% on room air 5. Significant cardiovascular disease such as New York Heart Association Class III or IV or Objective Class C or D cardiac disease (see appendix 07) 6. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 6 months of enrollment 7. History of severe immediate hypersensitivity reaction to any of the agents used in this study 8. Current treatment with strong CYP3A4/5 modulators (see appendix 13) 9. Pregnant, planning to become pregnant or lactating Women of Child Bearing Potential 10. Any significant medical conditions, laboratory abnormality or psychiatric illness likely to interfere with participation in this clinical study (according to the investigator's decision) 11. Person deprived of his/her liberty by a judicial or administrative decision 12. Person hospitalized without consent 13. Adult person under legal protection

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
golcadomide
golcadomide 0.3 mg weekly from D+5 post CAR T-cells administration until D+166

Locations

Country Name City State
France Hopital Henri Mondor Créteil
France Chu Dijon Bourgogne Dijon
France Chu de Grenoble La Tronche
France Chru de Lille Lille
France Institut Paoli Calmettes Marseille
France Chu de Montpellier Montpellier
France Chu de Nantes Nantes
France Hopital Saint-Louis Paris
France Chu de Bordeaux Pessac
France Chu Pontchaillou Rennes
France Centre Henri Becquerel Rouen
France Iuct Oncopole Toulouse
France Chu Brabois Vandœuvre-lès-Nancy

Sponsors (2)

Lead Sponsor Collaborator
The Lymphoma Academic Research Organisation Lymphoma Study Association

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Complete metabolic response rate (CMR rate) efficacy of golcadomide administered post-anti-CD19 CAR T-cell infusion 3 months
Secondary Objective response rate (ORR) incidence of either a complete (CMR) or a partial (PMR) metabolic response per the Lugano Classification (Cheson 2014) as determined by study investigators at 1 month, 3 months, 6 months, 1 year and 2 years, from CAR-T infusion
Secondary Objective response rate (ORR) determined by imaging central review at 1 month and 3 months
Secondary Complete response rate (CRR) percentage of complete response determined by investigator assessment classification at 1 Month, 6 Months, 1 year, and 2 years
Secondary Duration of response (DR) time from attainment of PMR or CMR to the date of first documented disease progression/relapse (based on investigator disease assessment (INV)) or death from any cause 2 years
Secondary Event-free survival (EFS) the time between CAR T-cells injection and death, disease progression, or start of subsequent new anti-lymphoma therapy including Stem Cell Transplant (SCT) 2 years
Secondary Progression-free survival (PFS) time from CAR T-cells injection to the first observation of documented disease progression/relapse (based on investigator disease assessment (INV)) or death 2 years
Secondary Time To Next anti-Lymphoma Treatment (TTNLT) from the date of CAR T-cells injection to the date of first documented administration of any new anti-lymphoma treatment 2 years
Secondary Overall survival (OS) from date of CAR T-cells injection to the date of death 2 years
Secondary Incidence of Adverse Events and Serious Adverse events 2 years
See also
  Status Clinical Trial Phase
Completed NCT03309878 - Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma Phase 1/Phase 2
Recruiting NCT05025800 - ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma Phase 1/Phase 2
Recruiting NCT04205838 - Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma Phase 2
Recruiting NCT05418088 - Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Phase 1
Recruiting NCT06343376 - Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Phase 1
Completed NCT04432506 - Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma Phase 2
Not yet recruiting NCT05077527 - Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma Phase 1
Recruiting NCT05672251 - Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Phase 2
Recruiting NCT05075603 - Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy Phase 1
Recruiting NCT04870853 - Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy
Recruiting NCT05507541 - TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Phase 2
Completed NCT04409314 - Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy